factual
Generics Only Need Show Bioequivalence
Hatch-Waxman's key reform allowed generic companies to rely on the brand-name drug's already-proven safety and efficacy: the brand must show the drug is safe and works, but the generic only has to show bioequivalence—that its product is the same as the approved drug—avoiding the absurdity of repeating years of clinical trials on an identical chemical.
factualpending
Speaker
Robin FeldmanEvidence Quote
“The generic just has to show bio-equivalence. So, in simplified terms, the first company has to show that the drug is safe and works. The second company just has to say, 'I'm the same. Me, too.'”
Created: 6/13/2026, 12:11:23 AM
Your notes
Loading notes...